-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Oxaliplatin (L-OHP) is a third-generation platinum compound and a commonly used chemotherapy drug for colorectal cancer
Oxaliplatin (L-OHP) is a third-generation platinum compound and a commonly used chemotherapy drug for colorectal cancer
The prospective GWAS study included 1379 patients with stage II/III colon cancer who received L-OHP-based (mFOLFOX6/CAPOX) adjuvant chemotherapy in a phase II (JOIN/JFMC41) or phase III (ACHIVE/JFMC47) trial
The prospective GWAS study included 1379 patients with stage II/III colon cancer who received L-OHP-based (mFOLFOX6/CAPOX) adjuvant chemotherapy in a phase II (JOIN/JFMC41) or phase III (ACHIVE/JFMC47) trial
Clinical features
Among the 1379 patients included in the GWAS analysis, the data of 1364 patients were analyzed
Among the 1379 patients included in the GWAS analysis, the data of 1364 patients were analyzed
The researchers then explored related SNPs that can predict the recovery time of PSN
The researchers then explored related SNPs that can predict the recovery time of PSN
The researchers then explored related SNPs that can predict oxaliplatin-mediated allergic reactions (AR)
The researchers then explored related SNPs that can predict oxaliplatin-mediated allergic reactions (AR)
Finally, GWAS explores related SNPs that can predict disease recurrence
In summary, the study failed to find meaningful SNPs that can predict oxaliplatin-mediated PSN, and there are greater clinical challenges in follow-up
Original source:
Kanai M, Kawaguchi T, Kotaka M, Manaka D, Hasegawa J, Takagane A, Munemoto Y, Kato T, Eto T, Touyama T, Matsui T, Shinozaki K, Matsumoto S, Mizushima T, Mori M, Sakamoto J, Ohtsu A , Yoshino T, Saji S, Matsuda F.
Kanai M, Kawaguchi T, Kotaka M, Manaka D, Hasegawa J, Takagane A, Munemoto Y, Kato T, Eto T, Touyama T, Matsui T, Shinozaki K, Matsumoto S, Mizushima T, Mori M, Sakamoto J, Ohtsu A , Yoshino T, Saji S, Matsuda F.
Large-scale prospective genome-wide association study of oxaliplatin in stage II/III colon cancer and neuropathy.
Ann Oncol.
2021 Nov;32(11):1434-1441.
doi: 10.
1016/ j.
annonc.
2021.
08.
1745.
Epub 2021 Aug 12.
PMID: 34391895.
Leave a message here
